Browse AMR Genes
Explore antimicrobial resistance genes from the literature
Explore antimicrobial resistance genes from the literature
negative regulator of MexCD-OprJ efflux pump
Overview
| Candidate |
| R21H | - | - | - | Ciprofloxacin | Reslit | Candidate |
| X188C | - | - | Pseudomonas aeruginosa | Ciprofloxacin | Reslit | Candidate |
| L26P | - | - | Pseudomonas aeruginosa | CiprofloxacinAzithromycin|Ciprofloxacin|Cefepime | Reslit | Candidate |
| R102G | - | - | Pseudomonas aeruginosa | Ciprofloxacin | Reslit | Candidate |
| Q67X | - | - | Pseudomonas aeruginosa | Ciprofloxacin | Reslit | Candidate |
| M115V | - | - | Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii | Delafloxacin|Gepotidacin|Omadacycline | Reslit | Candidate |
| E124A | - | - | Pseudomonas aeruginosa | Ciprofloxacin | Reslit | Candidate |
| F177S | - | - | Pseudomonas aeruginosa | Tobramycin|Aztreonam | Reslit | Candidate |
| H21P | - | - | Pseudomonas aeruginosa | Tobramycin|Aztreonam | Reslit | Candidate |
| E75K | - | - | Pseudomonas aeruginosa | Ciprofloxacin|Levofloxacin|Amikacin|Aztreonam|Fosfomycin | Reslit | Candidate |
| L456P | - | - | Pseudomonas aeruginosa | Ceftazidime-avibactam|Ceftolozane/tazobactam | Reslit | Candidate |
| A38G | - | efflux pump transcriptional repressor NfxB | Pseudomonas aeruginosa | QUINOLONE | Reference Gene Catalog | Established |
| R42H | - | efflux pump transcriptional repressor NfxB | Pseudomonas aeruginosa | COLISTIN | Reference Gene Catalog | Established |
| R42G | - | efflux pump transcriptional repressor NfxB | Pseudomonas aeruginosa | QUINOLONE | Reference Gene Catalog | Established |
| G155D | - | mutations in nfxB are known contributors to ciprofloxacin resistance | Pseudomonas aeruginosa | Ciprofloxacin | Reslit | Candidate |
| R82L | - | - | Pseudomonas aeruginosa | Ciprofloxacin|Norfloxacin | Reslit | Candidate |
| L83P | - | - | Pseudomonas aeruginosa | Azithromycin|Ciprofloxacin|Cefepime | Reslit | Candidate |
| G154D | - | - | Pseudomonas aeruginosa | Azithromycin|Ciprofloxacin|Cefepime | Reslit | Candidate |
| T39I | - | - | Pseudomonas aeruginosa | Azithromycin|Ciprofloxacin|Cefepime | Reslit | Candidate |
| A30V | - | - | Pseudomonas aeruginosa | Azithromycin|Ciprofloxacin|Cefepime | Reslit | Candidate |
| L178P | - | - | Pseudomonas aeruginosa | Azithromycin|Ciprofloxacin|Cefepime | Reslit | Candidate |
| L127P | - | - | Pseudomonas aeruginosa | Azithromycin|Ciprofloxacin|Cefepime | Reslit | Candidate |
| G180D | - | - | Pseudomonas aeruginosa | Azithromycin|Ciprofloxacin|Cefepime | Reslit | Candidate |
| R42L | - | - | Pseudomonas aeruginosa | Azithromycin|Ciprofloxacin|Cefepime | Reslit | Candidate |
| L29P | - | - | Pseudomonas aeruginosa | Azithromycin|Ciprofloxacin|Cefepime | Reslit | Candidate |
| - | - | Pseudomonas aeruginosa | Ciprofloxacin | Reslit | Candidate |
| - | loss-of-function | Pseudomonas aeruginosa | Ciprofloxacin | Reslit | Candidate |
| - | loss-of-function | Pseudomonas aeruginosa | Ciprofloxacin | Reslit | Candidate |
| - | loss-of-function | Pseudomonas aeruginosa | Ciprofloxacin | Reslit | Candidate |
| - | loss-of-function | Pseudomonas aeruginosa | Ciprofloxacin | Reslit | Candidate |
| - | overexpression of MexCD-OprJ efflux pump | Pseudomonas aeruginosa | Aminoglycoside|Colistin | Reslit | Candidate |
| - | loss-of-function | Pseudomonas aeruginosa | Ciprofloxacin | Reslit | Candidate |
| - | loss-of-function | Pseudomonas aeruginosa | Ciprofloxacin | Reslit | Candidate |
Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
The study identified nfxB mutations as a key mechanism for azithromycin resistance in Pseudomonas aeruginosa biofilms, leading to hyperexpression of the MexCD-OprJ efflux pump and cross-resistance to ciprofloxacin and cefepime.
Mechanisms decreasing in vitro susceptibility to the LpxC inhibitor CHIR-090 in the gram-negative pathogen Pseudomonas aeruginosa.
The study identifies several mechanisms by which Pseudomonas aeruginosa can reduce susceptibility to the LpxC inhibitor CHIR-090, including mutations in efflux pump regulators (mexR, nfxB, mexS), overexpression of LpxC, and mutations in the fatty acid biosynthesis gene fabG.
Genomics of adaptation during experimental evolution of the opportunistic pathogen Pseudomonas aeruginosa.
The study identifies several chromosomal mutations in P. aeruginosa that confer resistance to ciprofloxacin and adaptation to a CF-like environment, including mutations in gyrA, gyrB, nfxB, orfN, morA, wspF, and Pa14_56280.
Molecular mechanisms of master regulator VqsM mediating quorum-sensing and antibiotic resistance in Pseudomonas aeruginosa.
VqsM directly binds to the promoter regions of exsA and nfxB, regulating their expression and contributing to antibiotic resistance in Pseudomonas aeruginosa.
Evolution of Cost-Free Resistance under Fluctuating Drug Selection in Pseudomonas aeruginosa.
The study identifies mutations in nfxB, gyrA, and gyrB as key drivers of ciprofloxacin resistance in Pseudomonas aeruginosa under fluctuating drug selection, demonstrating that second-site mutations contribute to cost-free resistance.
History of antibiotic adaptation influences microbial evolutionary dynamics during subsequent treatment.
The study identifies various mutations in Pseudomonas aeruginosa that contribute to resistance against piperacillin, tobramycin, and ciprofloxacin, highlighting the impact of historical antibiotic exposure on subsequent resistance development.
Application of six multiplex PCR's among 200 clinical isolates of Pseudomonas aeruginosa for the detection of 20 drug resistance encoding genes.
The study identified several beta-lactamase genes (blaTem, blaOXA, blaCTX-M-15, blaVim, blaGes, blaVeb, blaDIM, AmpC) and efflux pump genes (MexA, MexB, OprM, MexC, MexD, OprJ, MexX, MexY, OprN, nfxB, MexR, OprD) in Pseudomonas aeruginosa clinical isolates, highlighting their roles in mediating resistance to various antibiotics.
A Large-Scale Whole-Genome Comparison Shows that Experimental Evolution in Response to Antibiotics Predicts Changes in Naturally Evolved Clinical Pseudomonas aeruginosa.
The study identifies multiple genes and mutations associated with antibiotic resistance in Pseudomonas aeruginosa through experimental evolution and whole-genome sequencing, highlighting the clinical relevance of these findings.
Low Ciprofloxacin Concentrations Select Multidrug-Resistant Mutants Overproducing Efflux Pumps in Clinical Isolates of Pseudomonas aeruginosa.
Low ciprofloxacin concentrations select for multidrug-resistant mutants in Pseudomonas aeruginosa clinical isolates, primarily through overproduction of efflux pumps mexCD-oprJ and mexEF-oprN, along with mutations in gyrA, parE, mexS, and nfxB.
Promoter regulatory mode evolution enhances the high multidrug resistance of tmexCD1-toprJ1.
The study identifies the tmexCD1-toprJ1 efflux pump gene cluster and its regulatory elements, showing that variations in the TNfxB and NfxB regulators and promoter regions contribute to multidrug resistance. Key mutations, such as T39R in TNfxB1, TNfxB3, and NfxB, weaken repressor function, enhancing efflux pump expression and resistance.
Targeting efflux pumps prevents the multi-step evolution of high-level resistance to fluoroquinolone in Pseudomonas aeruginosa.
The study identifies mutations in nfxB, gyrA, and gyrB as contributing to high-level fluoroquinolone resistance in Pseudomonas aeruginosa, with nfxB mutations playing a key role in antibiotic tolerance.
No comments yet. Be the first to comment!
© 2026 ResLit. Data sourced from PubMed literature analysis.
Built for antimicrobial resistance research